Eikon Therapeutics, Inc. Common Stock

Healthcare US EIKN

9.33USD
0.58(6.63%)

Last update at 2026-06-15T20:00:00Z

Day Range

8.959.89

LowHigh

52 Week Range

8.5817.40

LowHigh

Fundamentals

Previous Close 8.75
Market Cap625.30M
Volume316010
P/E Ratio-
Dividend Yield-%
EBITDA-295.55299M
Revenue TTM0.00000M
Revenue Per Share TTM-
Gross Profit TTM 0.00000M
Diluted EPS TTM-6.18

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-12-31	2024-12-31	2023-12-31
Type	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31
Income before tax	-324.24800M	-243.81400M	-241.99700M
Minority interest	-	-	-
Net income	-324.24800M	-243.81400M	-241.99700M
Selling general administrative	88.63M	55.81M	58.48M
Selling and marketing expenses	-	-	-
Gross profit	-	-	-
Reconciled depreciation	24.18M	25.39M	17.75M
Ebit	-	-	-
Ebitda	-	-	-
Depreciation and amortization	-	-	-
Non operating income net other	-	-	-
Operating income	-338.94500M	-260.34300M	-265.73700M
Other operating expenses	-	-	-
Interest expense	0.84M	0.03M	0.04M
Tax provision	-	-	-
Interest income	15.57M	16.56M	23.74M
Net interest income	14.73M	16.53M	23.70M
Extraordinary items	-	-	-
Non recurring	-	-	-
Other items	-	-	-
Income tax expense	-	-	-
Total revenue	0.00000M	0.00000M	0.00000M
Total operating expenses	338.94M	260.34M	265.74M
Cost of revenue	-	-	-
Total other income expense net	-0.03200M	-0.00300M	0.04M
Discontinued operations	-	-	-
Net income from continuing ops	-324.24800M	-243.81400M	-241.99700M
Net income applicable to common shares	-	-	-
Preferred stock and other adjustments	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31
Type	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31
Total assets	594.73M	491.24M	525.71M
Intangible assets	-	-	-
Earning assets	-	-	-
Other current assets	12.54M	7.38M	6.01M
Total liab	1473.77M	1063.17M	867.08M
Total stockholder equity	-879.03400M	-571.93000M	-341.37300M
Deferred long term liab	-	-	-
Other current liab	0.04M	0.30M	0.59M
Common stock	-	-	-
Capital stock	0.00000M	0.00000M	0.00000M
Retained earnings	-920.50900M	-604.94100M	-361.12700M
Other liab	-	-	-
Good will	-	-	-
Other assets	-	-	-
Cash	104.90M	129.18M	112.78M
Cash and equivalents	-	-	-
Total current liabilities	55.01M	56.45M	31.44M
Current deferred revenue	-	-	-
Net debt	-	-	-
Short term debt	-	-	-
Short long term debt	-	-	-
Short long term debt total	-	-	-
Other stockholder equity	-	-	-
Property plant equipment	-	-	-
Total current assets	348.92M	227.89M	436.43M
Long term investments	-	-	-
Net tangible assets	-	-	-
Short term investments	231.07M	90.93M	317.63M
Net receivables	-	-	-
Long term debt	-	-	-
Inventory	-	-	-
Accounts payable	0.68M	17.58M	2.19M
Total permanent equity	-	-	-
Noncontrolling interest in consolidated entity	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-
Accumulated other comprehensive income	-	-	-
Additional paid in capital	-	-	-
Common stock total equity	-	-	-
Preferred stock total equity	-	-	-
Retained earnings total equity	-	-	-
Treasury stock	-	-	-
Accumulated amortization	-	-	-
Non currrent assets other	8.35M	4.22M	2.40M
Deferred long term asset charges	-	-	-
Non current assets total	245.82M	263.35M	89.28M
Capital lease obligations	257.32M	202.46M	31.73M
Long term debt total	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31
Type	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31
Investments	-134.60200M	236.15M	165.46M
Change to liabilities	-	-	-
Total cashflows from investing activities	-	-	-
Net borrowings	-	-	-
Total cash from financing activities	352.05M	0.24M	105.81M
Change to operating activities	-	-	-
Net income	-324.24800M	-243.81400M	-241.99700M
Change in cash	-17.80600M	16.80M	51.91M
Begin period cash flow	130.88M	114.08M	62.17M
End period cash flow	113.07M	130.88M	114.08M
Total cash from operating activities	-188.51600M	-134.79900M	-190.84800M
Issuance of capital stock	352.05M	0.24M	105.81M
Depreciation	24.18M	25.39M	17.75M
Other cashflows from investing activities	-	-	-
Dividends paid	-	-	-
Change to inventory	-	-	-
Change to account receivables	-	-	-
Sale purchase of stock	-	-	-
Other cashflows from financing activities	-	-	-
Change to netincome	-	-	-
Capital expenditures	46.74M	84.80M	28.51M
Change receivables	-	-	-
Cash flows other operating	-	-	-
Exchange rate changes	-	-	-
Cash and cash equivalents changes	-	-	-
Change in working capital	77.83M	80.65M	9.98M
Stock based compensation	18.04M	12.43M	9.54M
Other non cash items	-5.54100M	-9.45600M	13.89M
Free cash flow	-235.25700M	-219.60200M	-219.36100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)
EIKN Eikon Therapeutics, Inc. Common Stock	0.58 6.63%	9.33	-	-	-	-
NVO Novo Nordisk A/S	0.04 0.09%	43.92	41.58	31.15	2.13	32.99	2.11	4.70
NONOF Novo Nordisk A/S	0.40 0.91%	44.40	41.06	31.25	2.08	33.11	2.11	4.70
VRTX Vertex Pharmaceuticals Inc	5.54 1.24%	450.46	29.67	24.33	10.38	5.83	9.33	20.00
REGN Regeneron Pharmaceuticals Inc	2.84 0.46%	614.98	29.07	20.12	7.57	3.82	6.95	19.42

Reports Covered

View All

Profile

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs using a platform that permits precise characterization of protein interactions in living cells. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.

Eikon Therapeutics, Inc. Common Stock

230 Harriet Tubman Way, Millbrae, CA, United States, 94030

341 777 0566
https://eikontx.com
Employees : 384

Key Executives

Name	Title	Year Born
Dr. Roger M. Perlmutter M.D., Ph.D.	Chairman, President & CEO	1952
Mr. Michael A. Klobuchar	Chief Operating Officer	1976
Dr. Roy D. Baynes FACP, M.D., Ph.D.	Executive VP & Chief Medical Officer	1955
Dr. Robert Tjian Ph.D.	Co-Founder & Member of Scientific Advisory Board	1949
Dr. Eric Betzig Ph.D.	Co-Founder & Member of Scientific Advisory Board	NA
Dr. Alfred Lloyd Bowie Jr., Ph.D.	Treasurer & CFO	1982
Mr. Russ Berman	Chief Technology Officer	NA
Mr. Benjamin Bruno Thorner	Secretary, General Counsel & Chief Business Officer	1971
Ms. Barbara Howes M.B.A.	Chief People Officer	1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Eikon Therapeutics, Inc. Common Stock

Healthcare US EIKN

9.33USD 0.58(6.63%)

Day Range

52 Week Range

Fundamentals

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Peer Comparison

Reports Covered

Stock Research & News

Profile

Eikon Therapeutics, Inc. Common Stock

Key Executives

9.33USD
0.58(6.63%)